Company Overview of Cempra, Inc.
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates include solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia, as well as for uncomplicated bacterial urethritis; and Taksta (CEM-102), an antibiotic that has completed Phase II clinical trials for refractory bone and joint infections. The company also produces novel macrolides for non-antibiotic uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has colla...
6320 Quadrangle Drive
Chapel Hill, NC 27517
Founded in 2005
Key Executives for Cempra, Inc.
Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $475.0K
Chief Financial Officer and Executive Vice President
Total Annual Compensation: $325.0K
Chief Commercialization Officer and Executive Vice President
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.
Cempra, Inc. Key Developments
Food and Drug Administration Grants Qualified Infectious Disease Product Designation to Cempra's Taksta Fusidic Acid Antibiotic
Sep 18 15
Cempra, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted a qualified infectious disease product (QIDP) designation to Cempra's investigational antibiotic product candidate, Taksta™ (CEM-102, sodium fusidate, the sodium salt of fusidic acid). The designation is for Taksta oral tablets for the indication of acute bacterial skin and skin structure infections (ABSSSI). The QIDP designation was created by the Generating Antibiotic Incentives Now (GAIN) Act of 2012. It provides certain incentives for the development of new anti-infectives, including eligibility for priority review, the FDA's Fast Track program, and a five-year extension of exclusivity under the Hatch-Waxman Act. The FDA has previously granted QIDP designation to Cempra's lead product development candidate solithromycin IV and capsules for the treatment of community acquired bacterial pneumonia (CABP) and solithromycin capsules for the treatment of gonorrhea.
Cempra, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 02:00 PM
Sep 3 15
Cempra, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 02:00 PM. Venue: Sofitel Hotel, New York, New York, United States. Speakers: Prabhavathi B. Fernandes, Founder, Chief Executive Officer, President and Director.
Cempra, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-16-2015 02:15 PM
Sep 3 15
Cempra, Inc. Presents at Morgan Stanley Global Healthcare Conference - New York, Sep-16-2015 02:15 PM. Venue: The Grand Hyatt New York, 109 East 42nd Street, New York, New York, United States. Speakers: Prabhavathi B. Fernandes, Founder, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|